PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs PF-06873600 (Primary) ; Hormone modulators
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 10 Oct 2019 Planned End Date changed from 29 Oct 2022 to 19 Mar 2023.
- 10 Oct 2019 Planned primary completion date changed from 29 Oct 2022 to 19 Mar 2023.
- 11 Aug 2019 Planned End Date changed from 25 Nov 2022 to 29 Oct 2022.